The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 124 participants.

Also called NCT06606821

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 124 participants (planned count) (from the registry)
Sponsor
Tina Vilsbøll (from the registry)
Registry
  • NCT NCT06606821
  • EU CT 2023-505270-15-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06606821. Randomized; triple masking; primary purpose treatment. Start 2024-10-01 (actual); primary completion 2027-03-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
Acronym
IDEAL-COR
Condition
Coronary Microvascular Dysfunction
Condition
Overweight or Obesity
Condition
Stable Angina Pectoris
Condition
Chronic Coronary Artery Disease
Condition
Atherosclerosis Cardiovascular Disease
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Placebo
Lead sponsor
Tina Vilsbøll (class: other)

Record details

Record id
cardio:ct-nct06606821
Content hash
5844a4e3856090d4c14c57052ef5c04de480abe5a6f14953f9960070d44bd026